Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Bexotegrast by Pliant Therapeutics for Liver Fibrosis: Likelihood of Approval
Bexotegrast is under clinical development by Pliant Therapeutics and currently in Phase II for Liver Fibrosis. According to GlobalData, Phase...
Bexotegrast by Pliant Therapeutics for Primary Sclerosing Cholangitis: Likelihood of Approval
Bexotegrast is under clinical development by Pliant Therapeutics and currently in Phase II for Primary Sclerosing Cholangitis. According to GlobalData,...
Bexotegrast by Pliant Therapeutics for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Bexotegrast is under clinical development by Pliant Therapeutics and currently in Phase III for Idiopathic Pulmonary Fibrosis. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Pliant Therapeutics's Bexotegrast?
Bexotegrast is a small molecule commercialized by Pliant Therapeutics, with a leading Phase III program in Idiopathic Pulmonary Fibrosis. According...